Case Report: Prolonged thrombocytopenia after chemotherapy in solid tumors requiring long-term thrombopoietin receptor agonist support: a five-patient case series. [PDF]
Front OncolWang S, Yu Y, Zhang L, Liu Q.
europepmc +1 more source
Chemotherapy-induced thrombocytopenia: from "platelet counting" to ecological repair of the bone marrow. [PDF]
Support Care CancerLiu T, Xie R, He Q, Ma J.
europepmc +1 more source
Sustained remissions off-treatment (SROTs) after tapering of thrombopoietin receptor agonists (TPO-RAs) have been reported in 15%–50% of patients with immune thrombocytopenia (ITP).
de Haas, Masja +15 more
core
2026 Korean expert recommendations for the use of thrombopoietin receptor agonists in severe aplastic anemia. [PDF]
Blood ResPark S +6 more
europepmc +1 more source
Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support. [PDF]
Front OncolQiao D, Nie L, Liu S, Ding HB.
europepmc +1 more source
Thrombopoietin agents and marrow fibrosis: fact or myth. [PDF]
HaematologicaBussel JB, Hyche MH.
europepmc +1 more source
Pharmaceutical Stability of Romiplostim: In-use Functional Study Using Microscale Thermophoresis New Strategy and Elisa. [PDF]
Pharm ResHermosilla J +6 more
europepmc +1 more source
Refractory Thrombocytopenia in TP53-Aberrant Chronic Lymphocytic Leukemia: A Multimechanistic Case with Response to Idelalisib and Romiplostim. [PDF]
J Clin MedGuven S, Kacar H, Seker O, Demirkan F.
europepmc +1 more source
Sustained Response After a Six-Week Course of Subcutaneous Daratumumab in Multi-Refractory Immune Thrombocytopenia. [PDF]
Mediterr J Hematol Infect DisGüllü Koca T, Yanık AM.
europepmc +1 more source
Evolving Patterns of TPO-RA Use in Children: A Decade of Single-Centre Experience and Narrative Review. [PDF]
Int J Mol SciUrbański B +8 more
europepmc +1 more source